Key Highlights
- 10.14% is the indicated pre-market decline for Evogene Ltd. (NASDAQ:EVGN) on November 17, 2026, with the price at USD 0.3520 against a calculated prior close of USD 0.3917, a calculated move of USD 0.0397.
- 9,316 thousand US dollars was the cash balance at June 30, 2026, down from USD 12,956 thousand at December 31, 2025, while 2026 cash usage guidance stands at USD 8.5 million to USD 9.5 million.
- 347 thousand US dollars was second quarter 2026 revenue, with Gross Profit of USD 141 thousand, an operating loss of USD 2,563 thousand and a net loss of USD 1,767 thousand, or USD 0.14 per share.
- 6 active Drug Development collaborations were reported on August 18, 2026, four of them added since the start of 2026, as headcount fell from 117 in December 2024 to 38 in August 2026.
What Moved Evogene Ltd. (NASDAQ:EVGN) in Pre-Market Trading on November 17, 2026 (-USD 0.0397, -10.14%)
The indicated pre-market price for Evogene Ltd. (NASDAQ:EVGN) is USD 0.3520 on November 17, 2026, a pre-market move of -10.14%. The calculated prior close is USD 0.3917 (USD 0.3520 divided by 0.8986), and the calculated USD move is -USD 0.0397. A corroborated market Capitalization was not found because a current share count was not located. Pre-market Volume was not found, and early sessions are typically thin.
The Rationale: No Single Catalyst Ahead of the November 19 Report for Evogene Ltd. (NASDAQ:EVGN)
No catalyst for the November 17, 2026 move was identified in published coverage. As general context, the company is expected to report third quarter results before the market opens on November 19, 2026, and positioning ahead of Earnings can add volatility. Consensus in published previews points to Revenue near USD 370 thousand and a loss of USD 0.19 per share. About USD 2.4 million was raised through at-the-market sales in the third quarter, which expands the share count. On September 30, 2026 Nasdaq granted an additional 180-day period to regain minimum bid price compliance.
Valuation, Liquidity and Risks for Evogene Ltd. (NASDAQ:EVGN)
First half 2026 revenue was USD 681 thousand, with a net loss of USD 7,663 thousand, or USD 0.67 per share, and net Research and Development spending of USD 2,938 thousand. Cash burn was about USD 14.4 million in 2025 and USD 20.5 million in 2024, with further reductions targeted for 2027. Weighted average shares were 12,199,883 in the second quarter, and ongoing at-the-market issuance signals dilution. With the price far below USD 1.00 and a small market value, the stock carries elevated Volatility and listing-compliance risk.
Where Things Stand
Evogene Ltd. (NASDAQ:EVGN) is indicated down 10.14% in pre-market trading on November 17, 2026, at USD 0.3520, a calculated drop of USD 0.0397 from a prior close of USD 0.3917. No specific catalyst was identified in published coverage, although third quarter results are expected before the open on November 19, 2026. Cash was USD 9,316 thousand at June 30, 2026, against 2026 usage guidance of USD 8.5 million to USD 9.5 million. Dilution from at-the-market sales and the Nasdaq bid price extension remain central risks. This article is informational and is not Investment advice.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...